论文部分内容阅读
目的比较拉米夫定与替比夫定治疗轻度乙型肝炎病毒感染对孕妇妊娠后期肝功能及母婴传播的影响差异。方法选取240例轻度乙型肝炎孕妇,按照治疗药物分为拉米夫定组、替比夫定组各120例。比较2组的孕妇妊娠后期肝功能以及母婴传播的情况。结果 2组丙氨酸氨基转移酶(ALT),天门冬氨酸氨基转移酶(AST),总蛋白(TP),白蛋白(ALB)等指标异常率差异无统计学意义(P>0.05)。2组HBV-DNA水平差异无统计学意义(P>0.05)。2组婴儿出生时及生后1年的HBs Ag阳性率、HBs Ab阳性率差异均无统计学意义(P<0.05)。结论拉米夫定和替比夫定治疗轻度乙型肝炎病毒感染对孕妇妊娠后期肝功能无显著影响,但是对母婴传播的阻断效果显著。虽然2组间差异无统计意义,但值得临床应用,对其疗效尚需进一步探讨。
Objective To compare the effects of lamivudine and telbivudine on mild hepatitis B virus infection in pregnant women during the second trimester pregnancy. Methods Totally 240 pregnant women with mild hepatitis B were divided into lamivudine group and 120 telbivudine group according to the therapeutic drugs. Comparison of the two groups of pregnant women during the second trimester of pregnancy liver function and mother-to-child transmission. Results The abnormal rates of ALT, AST, TP and ALB in the two groups had no significant difference (P> 0.05). There was no significant difference in HBV-DNA levels between the two groups (P> 0.05). There was no significant difference in HBsAg positive rate and HBs Ab positive rate between the two groups at birth and one year after birth (P <0.05). Conclusion Lamivudine and telbivudine treatment of mild hepatitis B virus infection in pregnant women with no significant effect on late pregnancy liver function, but the blocking effect on mother-to-child transmission was significant. Although no significant difference between the two groups, but it is worth clinical application, its efficacy needs further study.